Feature | February 28, 2013

Medtronic Gains European Approval for Engager Transcatheter Valve

New Valve Provides Transapical Option for Physicians Treating Patients with Aortic Stenosis

Engager TAVI valve

 

February 28, 2013 — Medtronic Inc. announced European CE (Conformité Européenne) mark approval for its Engager Transcatheter Aortic Valve Implantation (TAVI) System with transapical delivery catheter. The system is indicated to treat patients with severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement (SAVR).

The new valve demonstrated positive clinical outcomes in its European Pivotal Trial. Results from the multi-center trial, which were presented during late-breaking trial sessions at the recent European Association for Cardio-Thoracic Surgery and the Society of Thoracic Surgeons annual meetings, revealed high rates of procedural success, minimal paravalvular leak (PVL) and continuing clinical benefits for patients over time.

In the trial, the Engager valve was delivered transapically and had 94.3 percent overall device success (according to Valve Academic Research Consortium modified definitions). There were no procedures requiring a second valve and no occurrences of valve embolization, coronary obstruction or device malposition. No patients had moderate or severe PVL at six months, as measured by an independent echocardiography core lab. In addition, while most patients (88 percent) were NYHA Class III or IV at baseline, at six months 82 percent of patients had improved to NYHA Class I or II.

“The Engager valve has demonstrated exceptional clinical results, and by adding it to our transcatheter valve portfolio, we are providing heart teams with more options for achieving the best outcomes for every patient with severe aortic stenosis,” said John Liddicoat, M.D., senior vice president of Medtronic and president of the Medtronic structural heart business.

The Medtronic Engager System is not available in the United States.

The Engager valve uses a minimally?invasive delivery system via a catheter inserted in the apex (the lower, pointed end) of the heart. The valve is comprised of bovine tissue leaflets and a self?expanding nitinol frame designed to promote annular sealing to minimize paravalvular leak. Control arms simplify implantation, and the supra-annular valve positioning facilitates leaflet coaptation (connections) in non-circular anatomy for optimal hemodynamic performance. A direct aortic delivery system for Engager will be introduced in the future.

For more information: www.medtronic.com

 

Related Content

Mitralign, Percutaneous Tricuspid Valve Annuloplasty System

Mitralign's Percutaneous Tricuspid Valve Annuloplasty System uses catheter delivered pledgeted sutures that can be cinched together to change the valve annulus geometry to help eliminate valvular regurgitation. 

News | Heart Valve Repair| August 31, 2015
August 31, 2015 — Mitralign Inc. said the U.S.
melody valve

Max Page and his father Buck share a pre-operation moment on morning of July 30 Melody transcatheter valve procedure at Children's Hospital Los Angeles.

News | Structural Heart| August 28, 2015
August 28, 2015 — Cardiologists from Children’s Hospital Los Angeles successfully implanted a...
News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in

Mitral regurgitation viewed under color Doppler. Image courtesy of Toshiba.

Feature | Heart Valve Repair| August 26, 2015
August 25, 2015 — Medtronic announced it entered a definitive agreement to acquire Twelve Inc., a start–up medical de
Medtronic, CoreValve Evolut R, Loyola University Medical Center, first in Illinois, SURTAVI, EUS
News | Heart Valve Repair| August 19, 2015
Loyola University Medical Center is the first center in Illinois to implant the CoreValve Evolut R percutaneous aortic...
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
Mayo Clinic, LVAD, study, heart failure, restrictive cardiomyopathy, RCM

Thoratec HeartMate II image courtesy of Thoratec

News | Ventricular Assist Devices (VAD)| August 07, 2015
Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating...
Sponsored Content | Videos | Computed Tomography (CT)| August 07, 2015
DAIC Editor Dave Fornell shares some of the most innovative new technologies shown on the expo floor and discusses in
Overlay Init